Risk factors

The company relies heavily on licensed brands like Calvin Klein and Tommy Hilfiger, plus major department store customers like Macy's.

Company faces substantial operating losses and an accumulated deficit of $350.5 million as of December 31, 2024. Operations depend heavily on commercializing a small group of diagnostic tests including GraftAssureCore and DetermaIO. Revenues rely heavily on third-party payer coverage, Medicare billing policies, and FDA regulatory determinations for LDTs versus IVDs.

Revenue depends heavily on K-12 school districts and government contracts facing funding uncertainties. Growth relies on partner programs and acquiring software businesses. Profitability is pressured by labor costs and rapid AI competition.

Information technology operations heavily rely on private cloud data centers in Phoenix and Edison, and key software vendor Microsoft. Recent acquisitions such as NTS bring customer concentration, regulatory oversight, and integration hurdles. Intellectual property exposure includes an active lawsuit filed by Cisco Systems.

Clinical stage biotechnology company with operating losses and an accumulated deficit of $49.6 million.

Lowe's faces primary risks from intense competition, macroeconomic housing market sensitivity, and supply chain transformation execution. Rapidly evolving omnichannel expectations and technology adoption, including AI, introduce operational and regulatory vulnerabilities.

Larimar has incurred substantial losses since inception with an accumulated deficit of $269.2 million as of December 31, 2024. The company relies entirely on the clinical success and regulatory approval of its single lead product candidate, nomlabofusp. Existing cash of $183.5 million is expected to fund operations into the second quarter of 2026.

Lucid Diagnostics relies heavily on commercializing its lead EsoGuard and EsoCheck products for esophageal precancer testing.

Innovative Eyewear relies heavily on co-branded collections with Nautica, Eddie Bauer, and Reebok to drive growth in smart glasses. The company faces ongoing net losses, accumulating a deficit of $24,735,930 by the end of 2024. Manufacturing and supply chains depend entirely on limited third-party suppliers and a single optical lab located mainly in China and the U.S.

Meridian Holdings faces substantial financing obligations including $19,870,460 in Meridian Purchase Agreement payments and a $9,600,000 Secured Convertible Note balance. Operations rely on international markets, foreign currency transactions, and four primary resale customers.

Nephros carries an accumulated deficit of $144.3 million and depends heavily on single-source supplier Medica S.p.A. for filter materials. Revenue is concentrated in volatile emergency response waterborne pathogen outbreaks and relies on a tiny two-person management team.

Company is a clinical-stage biotechnology firm with cumulative net losses of $262.3 million from inception through December 31, 2024. Operations are heavily dependent on the lead gene therapy candidate NGN-401 using AAV9 delivery. The portfolio faces intense intellectual property protection needs and manufacturing complexities at its Houston facility.